DeutschNewstral
Article
bizjournals.com on 2016-09-27 15:46
Austin drugmaker's stock falters after latest FDA rejection
Related news
- Cempra's stock down over FDA rejectionbizjournals.com
- Acer Therapeutics stock plummets 80 percent on FDA rejectionbizjournals.com
FDA rejects drugmaker's much-anticipated arthritis pillWBNS-10TV- European regulators raise questions about Austin drugmaker's lead cancer treatmentbizjournals.com
- BSarepta Got a Scathing FDA Rejection and Its Stock Is Fallingbarrons.com
- Austin experts weigh in on convalescent plasma after FDA authorizationbizjournals.com
- TransEnterix raised $26M leading up to FDA rejectionbizjournals.com
- FDA tells doctors to 'closely monitor' patients who use weight-loss balloon from Austin companybizjournals.com
- BAcadia Is Hit by Wave of Downgrades After FDA Rejectionbarrons.com
Austin woman’s suffering reveals faults in how FDA approves medical devicesKVUE News- Ocular Therapeutix replaces regulatory chief after FDA rejectionbizjournals.com
- Cambridge's Akcea discloses layoffs after FDA drug rejectionbizjournals.com
- Bedford’s Ocular Therapeutix turns to layoffs after FDA rejectionbizjournals.com
- FFDA arthritis drug rejection hits Eli Lilly sharesft.com
- Alkermes blames drug rejection on Covid halting FDA inspectionsbizjournals.com
- Drugmaker with new Waltham offices vows to fight FDA rejectionbizjournals.com
- FDA warned Intarcia about manufacturing issues before drug rejectionbizjournals.com
- Following FDA rejection, Akebia lays off 180 workersbizjournals.com
- 'Ow, it's pokey ... That's it? You literally just touched me' | Austin children receive COVID-19 vaccines after FDA approvalKVUE News
- Approved: TransEnterix stock spikes on FDA clearancebizjournals.com